Ephenidine
Ephenidine (NEDPA) is a diarylethylamine dissociative and NMDA receptor antagonist that appeared as a research chemical in the mid-2010s. It produces dose-dependent dissociation, stimulation and anaesthesia, with human information limited to anecdote and a small number of pharmacology studies. It is typically taken orally.
01 Overview
Ephenidine is structurally related to diphenidine and shares its NMDA-antagonist mechanism. A handful of preclinical studies have examined its receptor binding, but there are no controlled human trials, and effects are known mainly from user reports.
At lower doses it produces stimulation and light dissociation; higher doses give heavy dissociation, ataxia, confusion and dissociative anaesthesia. Duration is moderate to long, and redosing on a slow onset can lead to overdose.
02 Mechanism
Non-competitive NMDA receptor antagonist binding within the ion channel; a diarylethylamine dissociative.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 50–80 mg | Oral | Slow onset; wait before considering more. |
| Common | 80–150 mg | Oral | Estimated from anecdote. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| DissociationDetachment, depersonalisation and derealisation. | Anecdotal | ||
| Stimulation and euphoriaEnergising, sometimes euphoric effect at lower doses. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Ataxia and loss of coordinationUnsteady gait and impaired motor control with fall risk. | Moderate | Very common | Anecdotal | |
| Confusion and agitationDisorientation, confusion and occasional agitation at high doses. | Moderate | At higher doses | Anecdotal |